纵向血清和多巴胺结合:对帕金森病进展和利沃多巴失运动症的影响
Eun Hye Jeong1, Jae Yong Lee1, Yoo Sung Song2,3
1Department of Neurology, Bundang Jesaeng General Hospital, Seongnam-si, Republic of Korea.
概括
帕金森病患者在四年内表现出血清素和多巴胺转运器比率的下降. 中脑中血清素载体水平可能预测勒沃多巴诱导的运动障碍的发展.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 运动障碍 运动障碍
背景情况:
- 帕金森病 (PD) 涉及进步的神经退行,影响运动功能.
- 血清和多巴胺系统对于运动控制至关重要,并且在PD中受到影响.
- 研究这些系统之间的相互作用可能会揭示补偿机制和疾病进展标志物.
研究的目的:
- 在帕金森病 (PD) 患者中,研究四年内血清和多巴胺特异性结合载体比率 (SBR) 之间的关系.
- 评估血清激素内在多巴胺激素内的潜在补偿作用.
- 确定SBRs与PD症状的关联以及Levodopa诱导的运动障碍症 (LID) 的发展.
主要方法:
- [I-123] N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane SPECT成像用于在基线和四年后评估中脑和条纹SBR.
- 分析了SBR和PD症状 (Hoehn和Yahr分期,MDS-UPDRS) 之间的相关性.
- 评估了SBR的变化及其与疾病进展和LID发展的关联.
主要成果:
- 在四年内,PD患者的运动功能显著恶化 (Hoehn和Yahr,MDS-UPDRS II和III) 以及中脑和条纹SBRs的下降.
- 中脑和条纹SBR在基线和随访时都显示出显著的相关性.
- 在四年后的下门和中脑SBR与LID的发展有关.
结论:
- 在PD患者中,中脑和门SBR与四年内运动症状严重程度 (MDS-UPDRS) 相相关.
- 中脑的血清素载体功能障碍与勒沃多巴诱导的运动障碍症的发病有关.
- 这些发现凸显了血清变化在PD进展和治疗并发症中的作用.
相关概念视频
01:24Parkinson's Disease: Treatment
206
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
206
01:15Parkinson's Disease: Overview
463
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
463
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:21Drugs Affecting Neurotransmitter Release or Uptake
931
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
931
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
249
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
249
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
78
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
78